共 50 条
- [21] Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Bauman, Julie E.Duwuri, UmamaheswarFerris, Robert L.Ohr, JamesGooding, William E.Kim, SeungwonJohnson, Jonas TalmadgeGrandis, Jennifer R.Stabile, Laura P.
- [22] Atypical new metastatic sites after immunotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M H&NSCC)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Deeken, John F.Ahmadi, MahsaJohnston, LauraHeyer, David M.Lee, PattyNiknia, KatherineBajaj, Gopal Krishna
- [23] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Safety results of a phase I/II studyJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7Chung, ChristineBonomi, MarceloSteuer, ConorSchell, MichaelLi, JiannongJohnson, MatthewMcMullen, CaitlinWadsworth, J. TradPatel, KrupalKish, JulieMuzaffar, JameelKirtane, KedarRocco, JamesSaba, Nabil
- [24] Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Ji, DongmeiSang, YouzhouLiu, XinGuo, YanjingYang, YananChen, GuangliangDong, ShuWang, YulongHe, XiayunYing, HongmeiLu, XueguanWang, YuHu, ChaosuJi, Qinghai
- [25] Impact of antibiotic use and derived neutrophil to lymphocyte ratio (dNLR) in patients with recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC) treated with immunotherapyANNALS OF ONCOLOGY, 2020, 31 : S675 - S675Plana, M.Cefarelli, G.Guillen, P.Esteve, A.Oliva, M.Gonzalez, A.Brenes, J.Vilarino, N.Vilajosana, E.Gomez, V.Mesia, R.Taberna, M.
- [26] Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 StudyINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E42 - E42Harrington, K.Kim, H. R.Salas, S.Oliva, M.Metcalf, R.Bernsdorf, M.Kim, J. W.Cohen, E.Siu, L. L.Rischin, D.Licitra, L.Vermorken, J.Le, Q. T.Tahara, M.Machiels, J. P.O'Hara, K.Pathiraja, K.Gumuscu, B.Bidadi, B.Burtness, B.
- [27] Radiomic response evaluation of recurrent or metastatic head and neck squamous cell cancer (R/M HNSCC) patients receiving pembrolizumab on KEYNOTE-012 study.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Taylor, KirstyKazmierski, MichalBillfalk-Kelly, AstridKhodakarami, FarnooshDriscoll, BrandonWang, LisaBratman, Scott VictorHaibe-Kains, BenjaminSiu, Lillian L.
- [28] Safety and efficacy of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase Ib/II studyANNALS OF ONCOLOGY, 2024, 35 : S625 - S625Guo, Y.Li, D. Z.Lin, J.Sun, C.Cao, G.Wu, J.Ge, M.Hu, D.Qu, S.Shen, L.Wei, Y.Zong, J.Fang, M.Jin, C.Li, Z-M.Sun, Y.Wang, X.Zhang, H.Wang, W.Zhu, Y.
- [29] Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapyANNALS OF ONCOLOGY, 2020, 31 : S668 - S668Carinato, H.Burgy, M.Fischbach, C.Kalish-Weindling, M.Pabst, L.Frasie, V.Thiery, A.Coliat, P.Demarchi, M. F.Petit, T.Borel, C.
- [30] Updated results of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase Ib/II studyANNALS OF ONCOLOGY, 2024, 35 : S1560 - S1560Guo, Y.Li, D. Z.Lin, J.Sun, C.Cao, G.Wu, J.Ge, M.Hu, D.Qu, S.Shen, L.Wei, Y.Zong, J.Fang, M.Jin, C.Li, Z. -m.Sun, Y.Wang, X.Zhang, H.Wang, W.Zhu, Y.